Abcam, ab226243, Anti-AHSG antibody [EPR17839-163] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FETUA antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR17839-163,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:IP, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab226243 is the carrier-free version of
ab187051
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target AHSG also known as fetuin-A or alpha-2-HS-glycoprotein is a multifunctional glycoprotein with an approximate mass of 64-68 kDa. It is mainly expressed in the liver and secreted into the bloodstream. AHSG exhibits a wide range of interactions with different cell types and biological molecules playing key roles in mineralization inhibition of arterial calcification and modulation of immune responses.
Biological function summary
AHSG protein serves multiple functions including acting as an inhibitor of insulin receptor autophosphorylation and serine-threonine kinase activities. AHSG is part of a complex dynamic process involving calcium metabolism and bone mineralization. It binds to transforming growth factor-beta (TGF-β) and other proteins modulating cellular signals and maintaining homeostasis in tissues. The regulation of calcium ion balance by AHSG can protect against ectopic calcification preventing potential damage.
Pathways
Calcium signaling and the insulin signaling pathways integrate AHSG functions. AHSG interacts with proteins like insulin receptor and those in the canonical Wnt signaling pathway influencing glucose metabolism and bone development. The balance of its interactions in these pathways helps maintain metabolic homeostasis and skeletal integrity reflecting its versatile roles within complex networks.
AHSG has connections to metabolic syndrome and calcific aortic valve disease. Abnormal levels of AHSG can disrupt metabolic functions and contribute to type 2 diabetes development by affecting insulin receptor activity. It also associates with calcification-related proteins in vascular tissues linking it to cardiovascular diseases. Understanding these connections is important for potential therapeutic targeting of AHSG in related pathologies.